دستورالعمل ارسال مقالات

Abstract Submission Guidelines

Time Table

  1. Submission Regulations
      • Abstract submission deadline for ISRO 2023 is on December 29, 2022.
      • Abstracts must be submitted online via the http://submit.iscocongress.com.
      • In case of abstract withdrawal, please submit your requests in writing via email to farazmand@iscocongress.com by January 05, 2023, with your submission ID number(s).
      • For any questions regarding the online submission process, please email farazmand@iscocongress.com.
  1. Aim and Scope

3.1. Clinical abstracts:

      • Breast cancer
      • CNS tumors
      • Cancer management in COVID-19 era
      • Cancer screening
      • Endocrine and neuroendocrine tumors
      • Gastrointestinal cancers
      • Genitourinary cancers
      • Gynecology cancers
      • Head and neck cancers
      • Hematological malignancies
      • Lung cancers
      • Palliative care
      • Psyco-oncology
      • Pediatric tumors
      • Sarcoma
      • Skin cancers

3.2. Physics abstracts:

3.3. Radiobiology abstracts:

      • Normal tissue radiobiology
      • Tumor radiobiology
      • Immuno-radiobiology
      • Microenvironment

3.4. RTT abstracts:

  1. Criteria for acceptance

4.1. Originality:

By submitting an abstract intended for presentation at ISRO 2023, the first author (= presenter) warrants that the materials have not been previously published in any publication (in peer review setting) before February 15, 2023.

4.2. Accepted manuscript formats

      • Original research
      • Systematic review
      • Meta-analysis
      • We will not consider:
        • Reviews
        • Case reports/case series
        • Hypothesis or proposal papers
        • Letters, commentaries, or essays
        • Opinion pieces
        • Policy papers
        • Clinical practice guidelines
        • Any other type of secondary literature
        • Monographs

4.3. Abstract structure

      • Author names and affiliations should not be present in the abstract title and abstract content as the abstract must be blinded for review.
      • The title of the abstract should include significant keywords that reflect the content of the abstract
      • Abstracts must not exceed 350 words. Deduct 50 words for each table, graphs or figures included. For example, with two figures, the maximum word count is 250.
      • Images are not permitted as they do not reproduce well. Brief and clear tables, graphs, and figures are accepted (maximum of 1 page on US Letter, 8.5 x 11-inch paper).
      • The abstract is presented in an intelligible fashion and is written in standard English
      • The abstract must include the main headings of Background and Objectives, Methods, Results, and Conclusions
      • Methods cover the main experiments and analysis (if any)
      • Results cover the findings on primary (and secondary, if any) objective
      • Conclusions are presented in an appropriate fashion and are supported by the data
      • Use generic terms for drug names
      • Standard abbreviations may be used without definition. Nonstandard abbreviations should be kept to a minimum and placed in parentheses after the first use of the word or phrase
      • Use International System (SI) for units
  1. Review Process
      • Each abstract will be blinded and scored by up to two reviewers.
      • The reviewers are selected based on the abstract category (clinical, physics, radiobiology, RTT)
      • Abstracts will be accepted on the basis of scientific merit and originality.
      • Overall, bear in mind that your abstract will be rated according to the following criteria:
      • is the design of the study valid?
      • are the methods appropriate?
      • what is the significance of the results?